文献速递血脂与心血管预防

依折麦布对75岁及以上人群动脉粥样硬化性心血管疾病一级预防的随机对照试验(EWTOPIA 75)

Ezetimibe Lipid-Lowering Trial on Prevention of Atherosclerotic Cardiovascular Disease in 75 or Older (EWTOPIA 75): A Randomized, Controlled Trial.
PubMed 文献 · Circulation · 2019-08-22

EWTOPIA 75 是一项在日本 363 家医疗机构开展的多中心、前瞻性、随机、开放标签、盲法终点评估试验,纳入 3796 例 ≥75 岁、LDL-C 升高且无冠心病史的患者,随机接受依折麦布 10 mg 每日一次或常规治疗。中位随访 4.1 年,依折麦布组主要复合终点(心源性猝死、心肌梗死、冠状动脉血运重建或卒中)发生率显著降低(HR 0.66,95%CI 0.50-0.86,P=0.002)。

要点

  • ≥75岁LDL-C升高且无冠心病史者,依折麦布降低主要心血管复合终点(HR 0.66)。
  • 复合心脏事件(HR 0.60)和冠状动脉血运重建(HR 0.38)也显著减少。
  • 卒中、全因死亡及不良事件发生率组间无差异;开放标签等局限需谨慎解读。

核心结论

  • 依折麦布降 LDL-C 治疗可预防 ≥75 岁、LDL-C 升高且无冠心病史患者的心血管事件,提示该人群 LDL-C 降低对一级预防的重要性。
  • 鉴于试验为开放标签、提前终止及随访问题,观察到的获益幅度应谨慎解读。

研究设计与样本

  • 多中心、前瞻性、随机、开放标签、盲法终点评估试验,在日本 363 家医疗机构开展。
  • 纳入 ≥75 岁、LDL-C 升高且无冠心病史的患者,全部接受饮食咨询,按 1:1 随机分配至依折麦布 10 mg 每日一次组或常规治疗组,随机化按中心、年龄、性别和基线 LDL-C 分层。
  • 因缺乏适当知情同意及其他方案违背,排除依折麦布组 182 例和对照组 203 例后,主要分析分别纳入 1716 例(90.4%)和 1695 例(89.3%)。

主要发现

  • 依折麦布降低主要终点(心源性猝死、心肌梗死、冠状动脉血运重建或卒中的复合终点)发生率(HR 0.66;95%CI 0.50-0.86;P=0.002)。
  • 依折麦布组复合心脏事件发生率低于对照组(HR 0.60;95%CI 0.37-0.98;P=0.039)。
  • 依折麦布组冠状动脉血运重建发生率低于对照组(HR 0.38;95%CI 0.18-0.79;P=0.007)。
  • 卒中、全因死亡或不良事件发生率在两组间无差异。

临床怎么用

  • 对 ≥75 岁、LDL-C 升高且无冠心病史的患者,可考虑使用依折麦布 10 mg 每日一次进行心血管事件一级预防。
  • 治疗决策时应结合饮食咨询,并注意该试验为开放标签、提前终止及随访问题,获益幅度需谨慎解读。

局限性

  • 试验为开放标签设计。
  • 试验提前终止。
  • 存在随访问题。
  • 观察到的获益幅度应谨慎解读。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Evidence regarding the primary prevention of coronary artery disease events by low-density lipoprotein cholesterol (LDL-C) lowering therapy in older individuals, aged ≥75 years, is insufficient. This trial tested whether LDL-C-lowering therapy with ezetimibe is useful for the primary prevention of cardiovascular events in older patients. METHODS: This multicenter, prospective, randomized, open-label, blinded end-point evaluation conducted at 363 medical institutions in Japan examined the preventive efficacy of ezetimibe for patients aged ≥75 years, with elevated LDL-C without history of coronary artery disease. Patients, who all received dietary counseling, were randomly assigned (1:1) to receive ezetimibe (10 mg once daily) versus usual care with randomization stratified by site, age, sex, and baseline LDL-C. The primary outcome was a composite of sudden cardiac death, myocardial infarction, coronary revascularization, or stroke. RESULTS: Overall, 3796 patients were enrolled between May 2009 and December 2014, and 1898 each were randomly assigned to ezetimibe versus control. Median follow-up was 4.1 years. After exclusion of 182 ezetimibe patients and 203 control patients because of lack of appropriate informed consent and other protocol violations, 1716 (90.4%) and 1695 (89.3%) patients were included in the primary analysis, respectively. Ezetimibe reduced the incidence of the primary outcome (hazard ratio [HR], 0.66; 95% CI, 0.50-0.86; P=0.002). Regarding the secondary outcomes, the incidences of composite cardiac events (HR, 0.60; 95% CI, 0.37-0.98; P=0.039) and coronary revascularization (HR, 0.38; 95% CI, 0.18-0.79; P=0.007) were lower in the ezetimibe group than in the control group; however, there was no difference in the incidence of stroke, all-cause mortality, or adverse events between trial groups. CONCLUSIONS: LDL-C-lowering therapy with ezetimibe prevented cardiovascular events, suggesting the importance of LDL-C lowering for primary prevention in individuals aged ≥75 years with elevated LDL-C. Given the open-label nature of the trial, its premature termination and issues with follow-up, the magnitude of benefit observed should be interpreted with caution. Clinical Registration: URL: https://www.umin.ac.jp. Unique identifier: UMIN000001988.

来源:Circulation,查看原文。版权归原作者所有。

引用

  1. Ouchi Y, Sasaki J, Arai H, et al. Ezetimibe Lipid-Lowering Trial on Prevention of Atherosclerotic Cardiovascular Disease in 75 or Older (EWTOPIA 75): A Randomized, Controlled Trial. Circulation. 2019. PMID: 31434507. doi:10.1161/CIRCULATIONAHA.118.039415

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。